Hereditary changes in genes are often the cause of rare diseases. For example, disease-causing gene variants (PVs) in the HRAS gene cause Costello syndrome and PVs in the KRAS gene cause Noonan ...
Phase 1 study of onalespib, HSP90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors. Background: Tipifarnib is a potent and highly selective inhibitor of ...
BOSTON and SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the ...
Gene mutations in the HRAS sequence are present in most patients affected with Costello syndrome, according to a new study in the American Journal of Medical Genetics. Gene mutations in the HRAS ...
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) Of the 22 patients with ...
– 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency ≥ 20% – – Median progression-free survival of 6.1 months vs. 2.8 months on last prior therapy – – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results